Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Cash from Operations (2018 - 2025)

Historic Cash from Operations for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to -$15.4 million.

  • Whitehawk Therapeutics' Cash from Operations rose 196.98% to -$15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$95.3 million, marking a year-over-year decrease of 7593.32%. This contributed to the annual value of -$59.6 million for FY2024, which is 18.94% up from last year.
  • Per Whitehawk Therapeutics' latest filing, its Cash from Operations stood at -$15.4 million for Q3 2025, which was up 196.98% from -$53.0 million recorded in Q2 2025.
  • Whitehawk Therapeutics' Cash from Operations' 5-year high stood at $10.6 million during Q1 2021, with a 5-year trough of -$53.0 million in Q2 2025.
  • For the 5-year period, Whitehawk Therapeutics' Cash from Operations averaged around -$14.3 million, with its median value being -$12.4 million (2021).
  • Per our database at Business Quant, Whitehawk Therapeutics' Cash from Operations skyrocketed by 36810.83% in 2021 and then crashed by 47832.26% in 2025.
  • Over the past 5 years, Whitehawk Therapeutics' Cash from Operations (Quarter) stood at -$12.4 million in 2021, then rose by 9.0% to -$11.3 million in 2022, then rose by 14.73% to -$9.6 million in 2023, then tumbled by 56.09% to -$15.1 million in 2024, then fell by 2.16% to -$15.4 million in 2025.
  • Its Cash from Operations stands at -$15.4 million for Q3 2025, versus -$53.0 million for Q2 2025 and -$11.9 million for Q1 2025.